nucleoside Reverse Transcriptase Inhibitor

nucleoside Reverse Transcriptase Inhibitors

NRTI

NRTIs

Reverse-transcriptase inhibitors (RTIs) are a class of antiretroviral drug used to treat HIV infection, tumors,[1] and cancer.[2] RTIs inhibit activity of reverse transcriptase, a viral DNA polymerase enzyme that retroviruses need to reproduce. ... Nucleoside analog reverse-transcriptase inhibitors (NARTIs or NRTIs) Nucleoside analog reverse-transcriptase inhibitors (NARTIs or NRTIs) compose the first class of antiretroviral drugs developed. In order to be incorporated into the viral DNA, NRTIs must be activated in the cell by the addition of three phosphate groups to their deoxyribose moiety, to form NRTI triphosphates. This phosphorylation step is carried out by cellular kinase enzymes. Zidovudine Zidovudine, also called AZT, ZDV, and azidothymidine, has the trade name Retrovir. Zidovudine was the first antiretroviral drug approved by the FDA for the treatment of HIV. Didanosine Didanosine, also called ddI, with the trade names Videx and Videx EC, was the second FDA-approved antiretroviral drug. It is an analog of adenosine. Zalcitabine Zalcitabine, also called ddC and dideoxycytidine, has the trade name Hivid. This drug has been discontinued by the manufacturer. Stavudine Stavudine, also called d4T, has trade names Zerit and Zerit XR. Lamivudine Lamivudine, also called 3TC, has the trade name Epivir. It is approved for the treatment of both HIV and hepatitis B. Abacavir Abacavir, also called ABC, has the trade name Ziagen, is an analog of guanosine. Emtricitabine Emtricitabine, also called FTC, has the trade name Emtriva (formerly Coviracil). Structurally similar to lamivudine, it is approved for the treatment of HIV and undergoing clinical trials for hepatitis B. Entecavir Entecavir, also called INN, is a guanine analog that has the trade name Baraclude. Though not currently approved as an HIV drug, entecavir is approved for the treatment of hepatitis B. Apricitabine Apricitabine, also called ATC. As of 2009, this drug is undergoing Phase-III evaluation, and if successful may achieve FDA approval in 2011. source: http://en.wikipedia.org/wiki/NNRTI

http://scai.fraunhofer.de/HuPSON#SCAIVPH_00001109

Reverse-transcriptase inhibitors (RTIs) are a class of antiretroviral drug used to treat HIV infection, tumors,[1] and cancer.[2] RTIs inhibit activity of reverse transcriptase, a viral DNA polymerase enzyme that retroviruses need to reproduce. ... Nucleoside analog reverse-transcriptase inhibitors (NARTIs or NRTIs) Nucleoside analog reverse-transcriptase inhibitors (NARTIs or NRTIs) compose the first class of antiretroviral drugs developed. In order to be incorporated into the viral DNA, NRTIs must be activated in the cell by the addition of three phosphate groups to their deoxyribose moiety, to form NRTI triphosphates. This phosphorylation step is carried out by cellular kinase enzymes. Zidovudine Zidovudine, also called AZT, ZDV, and azidothymidine, has the trade name Retrovir. Zidovudine was the first antiretroviral drug approved by the FDA for the treatment of HIV. Didanosine Didanosine, also called ddI, with the trade names Videx and Videx EC, was the second FDA-approved antiretroviral drug. It is an analog of adenosine. Zalcitabine Zalcitabine, also called ddC and dideoxycytidine, has the trade name Hivid. This drug has been discontinued by the manufacturer. Stavudine Stavudine, also called d4T, has trade names Zerit and Zerit XR. Lamivudine Lamivudine, also called 3TC, has the trade name Epivir. It is approved for the treatment of both HIV and hepatitis B. Abacavir Abacavir, also called ABC, has the trade name Ziagen, is an analog of guanosine. Emtricitabine Emtricitabine, also called FTC, has the trade name Emtriva (formerly Coviracil). Structurally similar to lamivudine, it is approved for the treatment of HIV and undergoing clinical trials for hepatitis B. Entecavir Entecavir, also called INN, is a guanine analog that has the trade name Baraclude. Though not currently approved as an HIV drug, entecavir is approved for the treatment of hepatitis B. Apricitabine Apricitabine, also called ATC. As of 2009, this drug is undergoing Phase-III evaluation, and if successful may achieve FDA approval in 2011. source: http://en.wikipedia.org/wiki/NNRTI

nucleoside Reverse Transcriptase Inhibitors

NRTI

NRTIs

nucleoside Reverse Transcriptase Inhibitor

hupson:SCAIVPH_00001109

nucleoside Reverse Transcriptase Inhibitor

http://purl.obolibrary.org/obo/CHEBI_35222